- Home
- WIW vs EVMN Comparison
WIW vs EVMN Comparison
Compare WIW & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WIW | EVMN |
|---|---|---|
| Founded | 2004 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 526.8M | 529.6M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | WIW | EVMN |
|---|---|---|
| Price | $8.57 | $19.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $39.17 |
| AVG Volume (30 Days) | 229.9K | ★ 322.0K |
| Earning Date | 01-01-0001 | 06-10-2026 |
| Dividend Yield | ★ 11.14% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,000,000.00 |
| Revenue This Year | N/A | $89.43 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 160.00 |
| 52 Week Low | $8.01 | $13.89 |
| 52 Week High | $9.37 | $24.03 |
Technical Indicators
Market Signals| Indicator | WIW | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 42.90 | 53.92 |
| Support Level | $8.54 | $16.36 |
| Resistance Level | $8.63 | $20.23 |
| Average True Range (ATR) | 0.03 | 1.82 |
| MACD | 0.00 | 0.09 |
| Stochastic Oscillator | 31.82 | 63.56 |
Price Performance
Historical ComparisonAbout WIW Western Asset Inflation-Linked Opportunities & Income Fund
Western Asset Inflation-Linked Opportunities and Income Fund is a diversified, closed-end management investment company. Its primary investment objective of the group is to provide current income for its shareholders. The secondary investment objective is capital appreciation with current income.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.